What precautions regarding renal function impairment should be considered when prescribing metformin in patients with chronic kidney disease?

Primary Safety Concern: Metformin-Associated Lactic Acidosis (MALA)

Metformin is renally cleared, and impaired kidney function leads to drug accumulation. Elevated tissue levels increase lactate production and reduce hepatic lactate clearance, driving metformin-associated lactic acidosis. A secondary precipitant (sepsis, hypoperfusion, liver disease, or hypoxaemia) is typically needed to trigger overt MALA, but mortality when it occurs historically approaches 50%. Risk factors compounding lactic acidosis risk include acute myocardial infarction, severe infection, respiratory disease, and liver disease.

eGFR-Based Dosing Thresholds

The dose framework and maximum daily dose ceilings below are from KDIGO 2022:

The KDIGO 2022 guideline recommends metformin for T2DM + CKD with eGFR ≥30, dose modification below eGFR 45, and cessation below eGFR 30. The ANZ CARI commentary on KDIGO 2022 suggests dose modification at eGFR <30 and discontinuation at eGFR <15, reflecting a more permissive Australian position than the main KDIGO recommendation.

Monitoring Requirements

• Baseline: Measure eGFR before initiating metformin.
• eGFR ≥60: Monitor annually.
• eGFR <60: Monitor every 3–6 months.
• Vitamin B12: Monitor for deficiency in patients on metformin for >4 years, or earlier if higher-risk (older patients, high daily dose, vegetarian or vegan diet, concurrent PPI, or new neuropathic symptoms), as B12 deficiency is a recognised long-term complication.
• Use eGFR, not serum creatinine alone, to guide dosing decisions.
• In patients with low or high body weight, BMI extremes, or rapidly changing kidney function, absolute kidney clearance (absolute mL/min, calculated by removing the standard 1.73 m² normalisation) may provide a more reliable estimate for dosing than indexed eGFR.

Acute Illness / "Sick Day" Precautions

Metformin is included in the SADMANS mnemonic (Sulfonylureas, ACE-inhibitors, Diuretics, Metformin, ARBs, NSAIDs, and SGLT2 inhibitors) as a drug that should be temporarily withheld during periods of acute illness or dehydration due to the risk of AKI and MALA. Kidney Health Australia recommends temporary interruption during ill health or any acute change in kidney function. Patients should have a documented sick-day action plan.

Iodinated Contrast Media

In patients with eGFR 30–60 ml/min/1.73m², temporarily withhold metformin at the time of iodinated contrast administration and for 48 hours afterwards; recheck renal function before recommencing to confirm eGFR has not fallen. In patients with eGFR <30, established AKI, or intra-arterial contrast with likely renal exposure, metformin should be withheld regardless of pre-contrast function. Purpose: to reduce the risk of contrast-associated AKI precipitating MALA. Aligns with RANZCR iodinated contrast media guidance and Kidney Health Australia recommendations.

Perioperative Withholding

Withhold metformin on the morning of major surgery (or from the day before, per local protocol) and resume once renal function is confirmed stable, the patient is eating and drinking normally, and there is no evidence of AKI or hypoperfusion. For minor procedures without significant fluid shifts or contrast exposure, metformin may generally be continued. Purpose: to avoid drug accumulation during periods of anaesthetic-induced haemodynamic change, fasting, and possible AKI.

Additional Considerations

• Fixed-dose combinations containing metformin (e.g. metformin-glibenclamide) also require dose review at reduced eGFR, taking into account the renal handling of both components.